Clinical Trial Update: Study of HPN424 in Patients With Advanced Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of HPN424 in advanced prostate cancer has been terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• HPN424 (HPN424)

Snippet

Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Advanced Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-02-14